Eswar Krishnan, MD
Drug Development Executive
Welcome to our podcast, designed specifically for biotech executives passionate about drug development. Join us as we explore a wide range of engaging topics, from cutting-edge advancements in translational sciences to the latest regulatory updates. Let’s navigate this dynamic landscape together and stay ahead of the curve! www.drugdevelop.com
Autor
Eswar Krishnan, MD
Categoría
Web del podcast
Último episodio
18 de jul. de 2025
¿Dónde escuchar?
Podcasts en la app Replaio Radio Muy prontoLos podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts
Instálala gratis
Android 5 M+ de descargas · valoración de 4,8
iOS muy pronto
Episodios
State Of The Art in SLE: For Biotech CMOs and CSOs 18.07.2025 45:47
This podcast summarizes the therapeutic landscape and the underlying molecular understanding of the causal pathways in lupus. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com
mAbs vs CAR-T: A Head-to-Head Comparison for CMOs and CSOs 14.07.2025 29:50
CAR-T Illustration. Courtesy New Scientist A recent head-to-head study assessed the comparative effectiveness of different B-cell depletion strategies in patients with autoimmune diseases, specifically comparing protein-based therapies like obinutuzumab (OBI), blinatumomab (BLI), and rituximab (RTX) with cell-based CD19 chimeric antigen receptor (CAR) T-cell therapy . Researchers analyzed lymph no...
Type 5 Diabetes: For CMOs and CSOs 07.07.2025 5:49
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com
B-cell depletion for autoimmune diseases: For Biotech CMOs and CSOs 06.07.2025 17:27
New B cell depleters in development may offer superior impact on the immune system, durably "reset" the immune system, potentially cure conditions like pre-Type 1 Diabetes and SLE, or allow celiac disease patients to tolerate gluten again. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com
Interleukin-6 and Cardioimmunology: For CMOs and CSOs 03.07.2025 16:27
This podcast discusses the role of inflammation, specifically interleukin-6 (IL-6) signaling, in cardiovascular diseases (CVD), including atherosclerosis and myocardial infarction (MI). We discuss the therapeutic potential of blocking IL-6 or its receptor (IL-6R) with drugs like tocilizumab and ziltivekimab, highlighting their ability to reduce inflammatory markers, such as C-reactive protein (CRP...
CAR T-Cell Therapy trials in Lupus just got a bit easier: For Biotech CMOs and CSOs 29.06.2025 48:16
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com
Fast Approvals with FDA's Voucher Programs: For Biotech CMOs and CSOs 29.06.2025 31:52
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com
Digital Twins For Biotech CMOs and CSOs 24.06.2025 40:59
This is an audio companion to the blog post in Substack This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com
Digital Twins for CSOs and CMOs 21.06.2025 40:59
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com
FDAs Recent Roundtable on Cell and Gene Therapies 08.06.2025 17:46
This podcast summarizes the FDA roundtable conducted on June 6, 2025. The original source is provided here This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com
Podcasts similares
Escucha el podcast Drug Development Executive en Replaio
Radio y podcasts en una sola app - gratis y sin registro. Instálala hoy y no te pierdas el estreno
Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos
